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Abstract: Phycotoxins are marine toxins produced by phytoplankton that can get accumulated 
in filter feeding shellfish. Human intoxication episodes occur due to contaminated seafood 
consumption. Okadaic acid (OA) and dynophysistoxins (DTXs) are phycotoxins responsible 
for a severe gastrointestinal syndrome called diarrheic shellfish poisoning (DSP). Yessotoxins 
(YTXs) are marine toxins initially included in the DSP class but currently classified as  
a separated group. Food safety authorities from several countries have regulated the content 
of DSPs and YTXs in shellfish to protect human health. In mice, OA and YTX have been 
associated with ultrastructural heart damage in vivo. Therefore, this study explored the 
potential of OA, DTX-1 and YTX to cause acute heart toxicity. Cardiotoxicity was evaluated 
in vitro by measuring hERG (human èter-a-go-go gene) channel activity and in vivo using 
electrocardiogram (ECG) recordings and cardiac damage biomarkers. The results demonstrated 
that these toxins do not exert acute effects on hERG channel activity. Additionally, in vivo 
experiments showed that these compounds do not alter cardiac biomarkers and ECG in rats 
OPEN ACCESS
Toxins 2015, 7 1031 
 
 
acutely. Despite the ultrastructural damage to the heart reported for these toxins, no acute 
alterations of heart function have been detected in vivo, suggesting a functional compensation in 
the short term. 




Marine algal blooms are natural phenomena caused by the overgrowth of marine phytoplankton. 
Presently, their appearance seems to have increased in frequency and severity, suggesting a public health 
problem of worldwide distribution. Some phytoplankton species present in these blooms produce 
phycotoxins that get accumulated in edible tissues of filter feeding shellfish through the marine food 
webs. Human intoxication episodes occur when contaminated seafood is consumed. 
Diarrhetic shellfish poisoning (DSP) is the toxic syndrome caused by the ingestion of shellfish 
contaminated with okadaic acid (OA) or its analogues, the dynophysistoxins (DTXs). OA and DTXs are 
marine lipophilic phycotoxins produced by dinoflagellates of the genera Prorocentrum and Dinophysis. 
DSP’s first episode was documented in Japan in the 1970s and since then, many episodes have been 
reported worldwide [1]. DSP is a severe gastrointestinal intoxication, of which the main symptoms are 
diarrhea, nausea, vomiting and abdominal cramps. Until now, no deaths have been related to acute or 
chronic toxicity of these toxins [2]. In order to protect human consumers, the presence of DSPs in 
seafood is regulated in many countries [3]. The mechanism of action of OA and DTXs is most likely 
related to the potent inhibition of serine/threonine protein phosphatases [4,5], which leads to 
hyperphosphorylation of cell proteins and dis-regulation of many cellular processes. Several 
toxicological studies with these compounds have described many effects at different cellular, molecular 
and genetic levels. In fact, they have been reported to cause cytotoxicity, neurotoxicity, immunotoxicity 
and embryotoxicity, as well as genotoxicity, tumor promotion and carcinogenicity [2]. 
Yessotoxins (YTXs) are polycyclic ether compounds produced by the phytoplanktonic dinoflagellates 
Protoceratium reticulatum, Lingulodinium polyedrum and Gonyaulux spinifera. YTXs were initially 
included in the DSP toxin class because they were detected simultaneously with OA and DTXs; 
however, nowadays they are classified and regulated separately owing to their different chemical 
structure, the lack of phosphatase inhibition activity and the absence of gastrointestinal toxicity [3]. 
Actually, and even though these toxins are also distributed worldwide, no human intoxication episodes 
have been related to the presence of yessotoxins in seafood [6]. In vivo toxicological studies in mice 
showed that yessotoxin causes alterations mainly in heart muscle [7–10]. On the other hand, in vitro data 
indicate that YTX induces apoptosis in many different cell lines, and it has been implicated in alterations 
of calcium movement [11], cyclic nucleotides and phosphodiesterases [12], or E-cadherin pathway and 
cytoskeleton [6,13]. Although the complete mechanism of action is not yet elucidated, the interaction of 
YTX with PDE4 is linked to the translocation to membrane and nucleus of the AKAP 149-PKA-PDE4A 
complex [14,15], being as well this effect linked to mTOR in apoptosis or autophagia [16]. 
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In spite of the reports of ultrastructural alterations of cardiac muscle after oral or intraperitoneal 
administrations of yessotoxin and okadaic acid in mice [7–10,17,18], the functional implications of these 
effects have not been studied. The evident mitochondrial damage in one of the tissues with the highest 
demands of energy suggests potential cardiotoxicity [7]. In fact, the recommendations of the last EFSA 
report on YTXs, elaborated by a panel of experts on this field, include the study of the toxicological 
significance of these ultrastructural changes described in the heart [19]. 
Guidelines for the evaluation of a compound potential cardiotoxicity can be found in the 
recommendations of the EMA [20] and in several articles [21,22], entailing both in vivo and in vitro 
experiments. The evaluation of the effect on hERG (human èter-a-go-go gene) channel function by patch 
clamp is the acute in vitro method of choice to assess cardiac safety in drug development [23]. HERG 
encodes the channel responsible for a critical current in cardiac action potential (AP) repolarization, the rapid 
delayed rectifier K+ current (IKr) [24]. Alterations of HERG channel currents have been related to the 
appearance of arrhythmias, specifically a type of fatal arrhythmia known as “Torsades de Pointes”  
(TdP) [25]. Additionally, some drugs can alter hERG by disruption of channel trafficking, but this is 
considered a chronic effect that usually takes hours or even days to occur [26]. Even though all cardiac 
channels contribute to the coordinated electrical activity of the heart, the implications on heart 
conductivity of hERG dysfunction have made hERG blockage evaluation essential to estimate potential 
cardiotoxicity. To evaluate in vivo heart toxicity, heart function and structural damage are considered. 
For functional alterations, electrocardiography is the technique of choice [21,22,27]. An electrocardiogram 
(ECG) represents the changes of electrical charge of the heart chambers for every beat; therefore it gives 
information about the overall electrical activity of the heart. The ECG may be altered by changes in 
biochemical and metabolic processes, by modifications of cardiac channels and cardiomyocyte 
membrane properties and by any structural injury that affect impulse generation and propagation [27]. 
In relation to structural damage, plasma cardiotoxicity biomarkers have also been recently included 
among the in vivo experiments for assessing cardiac toxicity [28]. Cardiac troponins I (cTnI) and  
T (cTnT) and the brain natriuretic peptide (BNP) are among the more accepted cardiac biomarkers 
nowadays [29,30]. 
Therefore, the aim of this work was to evaluate OA, DTX-1 and YTX acute cardiotoxicity using  
in vivo and in vitro methods. 
2. Results and Discussion 
2.1. OA and YTX Effects on hERG Channel Activity 
The ability to block hERG channel currents is one of the required tests for preliminary evaluation of 
cardiotoxicity in drug development. Therefore, the effects of OA and YTX (Figure 1) on hERG activity 
were explored using automated patch clamp for the measurement of hERG currents in a CHO cell line 
stably expressing this channel. HERG channels were activated with the voltage protocol shown in  
Figure 2A. After stabilization of hERG currents, the cells were exposed to 10 µM OA or YTX, or an 
equivalent concentration of DMSO (carrier) for 5 min. The Ionflux system warrants an immediate 
change of extracellular solution and therefore no time is needed to allow for drug diffusion. For routine 
screening of hERG inhibiting drugs it is common to test concentrations in this range that will cause a 
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clear and fast inhibition if the drug has high to medium blocking potency. A representative image of the 
current displayed by hERG CHO cells after YTX addition appears in Figure 2B. OA (Figure 2C, grey bar) 
and YTX (Figure 2D, grey bar) did not alter IKr amplitude after 5 minutes of exposure to a toxin 
concentration of 10 µM, when compared to the current in the same cells just before toxin addition. 
Similar results were obtained in cells exposed to carrier alone; no difference of IKr before and after 
addition of DMSO was observed (Figure 2C,D, white bars). DTX-1 (Figure 1) is an analog of OA and 
it has been described to have similar potency [1,31,32], thereby it was not tested in this assay to save the 
limited amount available for in vivo studies, which will provide information about potential 
cardiotoxicity generated by several possible mechanisms. Concentrations higher than 10 µM were not 
tested considering that compounds with an IC50 between 1 and 100 µM are classified as low potency 
hERG blockers and therefore would be pathologically irrelevant [33]. An underestimation of blocking 
potency due to technique limitations is not probable because the IC50 obtained for cisapride,  
a well-known high-potency hERG blocker, in our experimental conditions was 3 nM [34]. 
 
Figure 1. (A) Okadaic acid (OA); (B) dynophysistoxin-1 (DTX-1); (C) yessotoxin (YTX) 
chemical structures. 




Figure 2. Effects of OA, DTX-1 and YTX on human èter-a-go-go gene (hERG) channel 
activity. Automated patch clamp experiments were performed using a CHO cell line stably 
expressing hERG. (A) Voltage clamp protocol for the activation of hERG; (B) Representative 
current trace obtained after YTX addition. Currents were monitored for 5 min after toxin 
addition. COI: current of interest; (C) No effect of OA on hERG currents. Current magnitude 
is expressed as percentage of pre-treatment current that remained after 5 min of exposure to 
10 µM OA or carrier alone (mean ± SEM; n = 4); (D) No effect of YTX on hERG currents. 
Current magnitude is expressed as percentage of pre-treatment current that remained after  
5 min of exposure to 10 µM YTX or carrier (mean ± SEM; n = 4). 
2.2. Effects of OA, DTX-1 and YTX on Rat ECG 
Cardiotoxicity may be caused by many mechanisms different than hERG blockage. Therefore, studies 
of potential heart toxicity were performed in vivo. The animal model selected for this study was the  
rat, due to practical feasibility reasons, because, owing to its size, rats provided an adequate balance 
between toxin expense, a correct manipulation during surgery and catheter placement for blood sample 
collections and reliable ECG results in our experimental conditions. Moreover, females were used due 
to the smaller size of adult individuals in relation to males, which allowed reducing the expense of toxin. 
The toxins were administered intravenously because this administration route is the fastest  
and requires lower toxin amounts. The effects of OA, DTX-1 and YTX on heart functionality were 
evaluated by electrocardiography. Several ECG parameters were analyzed before and at different times 
after intravenous administration of each toxin. Lead II and an ECG recording speed of 50 mm/s were 
used to measure HR (bpm), PR interval, QT interval and T wave durations (ms) (Figure 3A). ECG 
activity was recorded before, and immediately and every hour after toxin administration. Each recording 
had a minimal length of 10 min (continuous) and the total experiment duration was 4 h. For these 
experiments five rats were injected with 20 µg/kg OA, five rats with 16 µg/kg DTX-1 and seven rats 
with 10 µg/kg YTX. Nine control rats followed the same experimental procedure with the administration 
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of carrier (DMSO in saline) in the absence of toxin. None of the ECG parameters evaluated were altered 
after the administration of OA, DTX-1, YTX or carrier (Figure 3B–E). Rodents have been widely used 
for cardiotoxicity evaluation and they share many similarities with humans in terms of pathophysiological 
changes or disease [27]; however, in humans hERG channel is an important player in heart action 
potential repolarization, and this is not the case in rodents. In vitro testing of hERG was included as a 
complement of cardiotoxicity evaluation due to this well-known difference. In addition, the macrolide 
antibiotic clarithromycin, which induces QTc prolongation, was previously used as a positive control for 
QTc interval prolongation in our experimental conditions; a dose of 2.2 mg/kg caused an increase of QTc 
duration of 19% ± 3% [35,36]. 
 
Figure 3. Effects of OA, DTX-1 and YTX on rat electrocardiogram (ECG). ECG 
parameters (HR, PR interval, QTc interval and T wave) were analyzed before and at different 
times after intravenous administration of 20 µg/kg OA to 5 rats, 16 µg/kg DTX-1 to 5 rats and 
10 µg/kg YTX to 7 rats. (A) Representative ECG recording at 50 mm/s. The landmarks and 
the measurements of PR interval, R-R interval, QT interval and T wave duration are indicated; 
(B) HR; (C) PR interval; (D) QTc interval and (E) T wave were measured for all treated rats 
in ECG recordings at the following times: −10 (before toxin administration), 0 (toxin 
administration), 50, 110, 170 and 230 min. At every time point ECG was recorded for 10 min. 
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Cardiac rhythm alterations were also analyzed. Type of arrhythmia, time of appearance from toxin 
administration, duration of arrhythmia sequences, total number of arrhythmia episodes, ECG recording 
duration and survival of the animal along the experiment are reported in Table 1. The rats administered 
with DTX-1 did not evidence any arrhythmia episode. However, 1/5 rat administered with OA, 2/7 rats 
administered with YTX and 2/9 rats administered with carrier showed the appearance of ventricular 
extrasystoles (VES). The total number of VES was 5 for OA-treated rats, 4 for YTX-treated rats and 3 
for controls. Three YTX-treated rats died prematurely during the experiment as judged by apnea onset, 
and one of them had 3 VES before death occurred. One OA-treated rat died during the experiment but it 
did not show VES. None of DTX-1 and carrier-treated rats died before the end of the experiment. 
Therefore, it does not seem to be a correlation between death and arrhythmia occurrence in  
these experiments. 
Table 1. Heart rhythm alterations in OA, DTX-1 and YTX-treated rats and controls. 
Rat Type 















1    0 265 no 
2    0 265 no 
3    0 265 no 
4    0 265 no 
5    0 265 no 
6 VES t68:45 3 2 265 no 
7 VES t52:31  1 265 no 
8    0 265 no 




10 0    265 no 
11 0    265 no 
12 
VES t110: 30 
66 
3 265 no 
VES t174:45 1 265 no 
VES t196:49 1 265 no 
13 0    130 yes 






15 0    265 no 
16 0    265 no 
17 0    265 no 
18 0    265 no 





20 0    160 yes 
21 0    265 no 
22 0    120 yes 
23 VES t236:08 1 1 265 no 
24 VES t77: 35 5 3 140 yes 
25 0    265 no 
26 0    265 no 
VES: ventricular extrasystole. 
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The i.v. doses used in this study were 1/10 of mouse intraperitoneal LD50 for OA and YTX and 1/10 
of mouse intraperitoneal MLD for DTX-1 (no lethality data available in rats) [32,37]. Actually, the i.v. 
dose of YTX is probably close to the LD50 by this route, since 3/7 rats died during the experiment.  
A fairly high dose was selected to be sure that if no effects were observed, there would be no need to 
repeat the experiment with a higher dose, since that kind of experimental design would require higher 
amounts of animals and toxin, and also to account for the possibly lower sensitivity of females to 
cardiovascular diseases and toxicity [38,39]. Thereby, if cardiotoxicity was an important component of 
acute YTX toxicity, some functional signs should have been observed at this dosing level. In the  
case of OA-treated rats, although this dose is clearly lower than the LD50, one death was recorded during 
the experiment. Therefore, this dose is enough to cause death of some individuals, but no cardiotoxicity 
signs were observed. DTX-1 toxic potency is considered similar to OA [1], although it might be higher 
by the oral route [40]. Thus, DTX-1 dosing levels would probably be sufficient to induce clinical signs 
if cardiotoxicity were an important component of DTX-1 toxicity. The lack of effects of YTX on the ECG 
is somehow surprising due to the abundant evidence of ultrastructural damage observed in cardiomyocytes 
of YTX-treated mice [7–10,17,18]. In fact, cardiomyocyte ultrastructural alterations have been described 
after intraperitoneal and oral administration of the toxin, even at doses that are far below the LD50 and 
at times as short as 1 h [8]. Furthermore, oral administrations of YTX at asymptomatic doses have 
demonstrated myocardial alterations at 24 h that persisted for at least 30 days [10,17]. The absence of 
effects on ECG recordings may be due to heart compensatory mechanisms to maintain functionality. 
Overall, OA, DTX-1 and YTX did not have in vivo functional effects on ECG parameters. Although 
some arrhythmia episodes were observed in toxin-treated rats, the frequency and number of animals 
affected were similar to controls, and therefore they would not be related to a toxin effect. Maintenance 
of functionality with this cardiomyocyte ultrastructural damage may not be feasible in the long term, 
considering that loss of cardiomyocyte function after injury is described as the principal etiology of heart 
failure [41], and therefore further studies are necessary to explore chronic cardiotoxic effects of  
these toxins. 
2.3. Effects of OA, DTX-1 and YTX on the Levels of Cardiac Biomarkers 
Quantification of plasma cardiotoxicity biomarkers has also been recently included among the 
experiments for assessing in vivo structural heart damage. The levels of the cardiac biomarkers cTnI, 
cTnT and BNP were measured in rats treated with OA, DTX-1 or carrier. The quantification of these 
biomarkers was done in plasma samples collected during ECG experiments using panel 1 of the rat 
cardiovascular disease (CVD) kit from Millipore®. Plasma samples from YTX-treated rats were analyzed 
only for cTnI with a specific ELISA kit. Control samples from rats that received just the carrier were 
also included in the assays. Several plasma samples were collected for each rat along the experiment; 
one before toxin administration and the others every hour after toxin administration (see Methods 
section). Rats treated with OA or DTX-1 did not evidence any increase of plasmatic cTnI, cTnT or BNP 
during the experiment (Figure 4A–C, grey bars). The rats that received only the carrier (Figure 4A–C, 
white bars) showed similar levels of these biomarkers. The results for YTX-treated rats demonstrated no 
increase of cTnI during the first four hours following intravenous administration of the toxin in 6 rats 
(Figure 4D, rats 21–26), with the exception of one rat (Figure 4D, rat 20). Actually, no statistically 
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significant differences were observed with regards to cardiac biomarkers in this study. In the case of  
rat 20, the animal entered apnea 140 min after toxin administration and cardiac activity continued for 
some time with increasing appearance of arrhythmias. Finally, the experiment was interrupted at time 
160 min and a blood sample was collected that showed an increased concentration of cTnI. This increase 
that occurred after apnea onset was probably due to hypoxia and it should not be considered a direct 
effect of YTX. Isoproterenol, which is known to cause an increase of plasmatic cTnI [42], was used as 
positive control in these experimental conditions [36]. Two rats were injected with 4 mg/kg isoproterenol 
and after 2 h cTnI plasma levels were increased 3 times [36]. The detection of elevated cTnI plasma 
levels post-apnea and in isoproterenol-treated rats served as positive controls for the performance of 
immuno-detection techniques and experiment duration. Because the levels of cardiac cTnI and cTnT in 
plasma of rats treated with OA, DTX-1 and YTX were not altered, important myocardial injury after the 
acute administration of these toxins can be excluded [30]. Additionally, BNP levels, which are indicative 
of hemodynamic changes, ventricular damage or stress [43] were also not increased by OA and DTX-1. 
 
Figure 4. Effects of OA, DTX-1 and YTX on the levels of cardiac biomarkers. Blood 
samples were collected before and at different times (60, 120, 180 and 240 min) after i.v. 
administration of toxin or carrier. For OA- and DTX-1-treated rats, cTnI, cTnT and BNP 
were quantified in plasma samples. For YTX-treated rats cTnI levels were measured. (A) cTnI; 
(B) cTnT and (C) BNP plasma levels measured in OA- (light grey bars) and DTX-1-treated 
rats (dark grey bars) and control rats (white bars) using immunodetection with a xMap rat 
CVD panel from Millipore®; (D) cTnI plasma levels measured in seven YTX- treated rats 
using a specific ELISA kit. (Mean ± SEM). 
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2.4. Effects on Biochemistry Parameters 
Heart dysfunction may be secondary to other organ damage. To provide a more complete 
pathophysiologic evaluation, several biochemical parameters were analyzed. A General Health Profile 
(GHP) prepacked panel was used to measure albumin (ALB), alkaline phosphatase (ALKP) alanine 
aminotransferase (ALT), blood urea nitrogen (BUN), calcium (Ca), cholesterol (CHOL), creatine kinase 
(CK), creatinine (CREA), globulin (GLOB), phosphorus (PHOS), and total protein (TP) in  
two plasma samples collected from each rat, one before toxin or carrier administration and the other after 
treatment, at the end of the experiment. The results are shown in Table 2. TP and ALB plasma levels 
were significantly lower after 4 h of experiment when compared to initial levels in all rats. GLOB levels 
were also decreased but only significantly in DMSO and DTX-1- treated rats. This reduction of TP, ALB 
and GLOB levels along the experiment was probably due to plasma dilution caused by fluid therapy. 
ALKP levels were also significantly reduced in all groups including controls. CHOL plasma levels were 
above normal values before DTX-1 administration and also before and after OA and YTX 
administrations. Additionally, CHOL levels were decreased at the end of the experiment in all rats; this 
lower values being statistically significant versus pre-treatment levels in YTX and DMSO-treated rats. 
Ca was slightly reduced at the end of the experiment in all groups. ALKP, CHOL or Ca decreases might 
also be explained by plasma dilution. In any case, the slight reductions observed in these parameters 
would not be clinically important in terms of organ functionality. CK levels were significantly elevated 
in OA and/or DMSO-treated rats; however they were always below normal values. ALT plasma levels 
seemed to elevate in DMSO, OA and YTX-treated rats, but only plasma concentrations of ALT in  
OA-treated rats reached values above the physiological range. ALT is the clinical chemistry gold 
standard of hepatotoxicity [44] and its increase would be in agreement with previously reported hepatic 
damage observed in rats after i.v. administration of OA [45]. BUN plasma levels were significantly 
increased and above the physiological range after OA and YTX treatment. Finally, CREA and PHOS 
plasma levels were within normal physiological values in all cases. CREA and BUN are the common 
biomarkers of nephrotoxicity and both are usually evaluated together when renal injury is  
diagnosed [46]. Our results did not show increased CREA levels, therefore BUN elevation might be 
indicative of incipient kidney damage but more parameters would be necessary to confirm a direct 
nephrotoxic action [46,47]. On the whole, these biochemical results showed only two alterations that 
could be related to the toxin treatment, the apparent ALT increase in OA-treated rats and the BUN 
increase in OA and YTX-treated rats. However none of these observations is definitely conclusive of 
liver or kidney damage. 
3. Experimental Section 
3.1. Chemicals and Solutions 
OA (purity ≥ 98.9%), DTX-1 (purity ≥ 98%) and YTX (purity ≥ 97.9%) certified reference materials 
(CRMs) were supplied by Laboratorio CIFGA S.A. (Lugo, Spain). Nut Mix F-12 W/GLUTAMAX-I 
medium, fetal bovine serum (FBS), geneticin, trypsin/EDTA, CHO cell serum free media (CHO-SFM) 
and Dulbecco’s phosphate-buffered saline (DPBS) were purchased from Invitrogen® (Eugene, OR, USA). 
Claritrhomycin (Klacid IV) was from Abbott Laboratories (Abbott Park, IL, USA). Isoproterenol 
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(Aleudrina) was from Laboratorio Reig Jofre (Barcelona, Spain). Trypan blue solution, dimethyl sulfoxide 
(DMSO) and cisapride monohydrate were from Sigma-Aldrich Química S.A. (St. Louis, MO, USA). 
DetachinTM was purchased from Labclinics (Barcelona, Spain). IonFlux extracellular solution (EC,  
145 NaCl, 4 KCl, 1 MgCl2, 2 CaCl2, 10 HEPES, 10 Glucose (mM)), IonFlux intracellular solution  
(IC, 60 KCl, 70 KF, 15 NaCl, 5 HEPES, 5 EGTA (mM)) and IonFlux 16-well plates were obtained from 
Fluxion Bioscences Inc. (South San Francisco, CA, USA). Sodium chloride solution 0.9% was from 
Grifols Engineering, S.A. (Barcelona, Spain). CVD Milliplex® Map KIT was from Millipore® Iberica 
S.A. (Billerica, MA, USA). General Health Profile (GHP) chemistry panel was obtained from IDEXX 
Laboratories (Barcelona, Spain). High sensitivity rat cardiac Troponin-I ELISA kit was from Life 
diagnostics (Wester Chester, PA, USA). 
Table 2. Plasmatic levels of biochemical markers in OA-, DTX-1- and YTX-treated rats and controls. 
Time 











BUN (mg/dL) 17 ± 1.0 23.7 ± 1.1 ** 20.3–25.5 
CREA (mg/dL) 0.4 ± 0.0 0.4 ± 0.0 0.5–0.92 
PHOS (mg(dL) 6.2 ± 0.2 6.4 ± 0.9 4.2–8.33 
Ca (mg/dL) 10.2 ± 0.1 10.1 ± 0.1 9.6–11.86 
TP (g/dL) 5.2 ± 0.1 3.9 ± 0.1 ** 5.00–7.7 
ALB (g/dL) 2.8 ± 0.1 1.9 ± 0.1 ** 2.9–4.6 
GLOB (g/dL) 2.4 ± 0.1 2.0 ± 0.1 ** 2.1–3.1 
ALT (U/L) 49.1 ± 10.9 52.2 ± 23.8 32.7–84.1 
ALKP (U/L) 130.4 ± 10.1 76.3 ± 6.5 ** 82.8–297.3 
CHOL (mg/dL) 59.1 ± 15.6 56 ± 2.2 * 41.1–59.1 








BUN (mg/dL) 18.3 ± 1.5 28.0 ± 0.9 ** 20.3–25.5 
CREA (mg/dL) 0.5 ± 0.1 0.6 ± 0.0 0.5–0.92 
PHOS (mg(dL) 6.9 ± 1.0 8.0 ± 0.7 4.2–8.33 
Ca (mg/dL) 10.2 ± 0.1 9.9 ± 0.1 * 9.6–11.86 
TP (g/dL) 5.5 ± 0.2 4.4 ± 0.1 ** 5.00–7.7 
ALB (g/dL) 2.8 ± 0.1 1.9 ± 0.1 ** 2.9–4.6 
GLOB (g/dL) 2.7 ± 0.1 2.5 ± 0.1 2.1–3.1 
ALT (U/L) 51.5 ± 8.6 95.6 ± 24.6 32.7–84.1 
ALKP (U/L) 110.7 ± 11.8 83 ± 8.3 * 82.8–297.3 
CHOL (mg/dL) 91.3 ± 7.3 69.6 ± 2.9 41.1–59.1 










BUN (mg/dL) 18 ± 1.1 25.0 ± 2.1 ** 20.3–25.5 
CREA (mg/dL) 0.3 ± 0.0 0.3 ± 0.0 0.5–0.92 
PHOS (mg(dL) 7.5 ± 0.4 7.5 ± 0.6 4.2–8.33 
Ca (mg/dL) 10.1 ± 0.1 9.0 ± 0.6 9.6–11.86 
TP (g/dL) 5.5 ± 0.1 4.2 ± 0.1 ** 5.00–7.7 
ALB (g/dL) 3.0 ± 0.1 2.0 ± 0.1 ** 2.9–4.6 
GLOB (g/dL) 2.5 ± 0.1 2.1 ± 0.1 * 2.1–3.1 
ALT (U/L) 34.5 ± 3.5 21.2 ± 6.2 32.7–84.1 
ALKP (U/L) 123.2 ± 13.7 78.8 ± 8.3 ** 82.8–297.3 
CHOL (mg/dL) 74.2 ± 4.2 58.2 ± 8.7 41.1–59.1 
CK (U/L) 113.6 ± 16.6 162.4 ± 26.4 494–4132 
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Table 2. Cont. 
Time 










BUN (mg/dL) 17.7 ± 1.3 29.8 ± 1.5 ** 20.3–25.5 
CREA (mg/dL) 0.5 ± 0.1 0.6 ± 0.2 0.5–0.92 
PHOS (mg(dL) 7.1 ± 1.4 7.0 ± 1.3 4.2–8.33 
Ca (mg/dL) 10.1 ± 0.0 9.5 ± 0.1 ** 9.6–11.86 
TP (g/dL) 5.4 ± 0.2 4.1 ± 0.1 ** 5.00–7.7 
ALB (g/dL) 2.6 ± 0.1 1.8 ± 0.1 ** 2.9–4.6 
GLOB (g/dL) 2.7 ± 0.1 2.5 ± 0.1 2.1–3.1 
ALT (U/L) 23.8 ± 4.5 30.8 ± 8.2 32.7–84.1 
ALKP (U/L) 113.8 ± 8.6 80 ± 6.4 ** 82.8–297.3 
CHOL (mg/dL) 82 ± 6.1 64.5 ± 2.9 ** 41.1–59.1 
CK (U/L) 151.3 ± 16.7 296 ± 119.0 494–4132 
* Statistically significant versus levels before administration. ** Statistically significant versus levels before 
administration and at least one of the values out of physiological range. 
3.2. Cell Line 
A PrecisionTMhERG CHO (Chinese hamster ovary) Recombinant cell line (Millipore®Iberica S.A., 
Madrid, Spain) was used for patch clamp experiments. HERG CHO cells were grown in Nut Mix F-12 
W/GLUTAMAX-I medium supplemented with 10% FBS and 400 μg/mL of geneticin (complete culture 
media) in a humidified 5% CO2 incubator at 37 °C. They were fed every 24–36 h and passaged every  
2–3 days (cell confluence never exceeded 80%). Prior to functional assays, the cell cultures were placed 
for at least two days at 30 °C in a humidified 5% CO2 incubator. 
3.3. Automated Patch Clamp 
The effect of these biotoxins on hERG channel activity was tested using an IonFlux 16 automated 
patch clamp system (Fluxion Bioscences Inc., South San Francisco, CA, USA). Current measurement 
experiments were performed in 16-well IonFlux plates that have 8 pairs of cell traps, each trap endowed 
with 20 trapping sites placed in parallel. 
The cells were washed twice with 5 mL of warm DPBS and detached by incubation with 5 mL of 
warm DetachinTM solution for 10 min at 37 °C. Immediately, 5 mL of warm CHO serum-free culture 
medium supplemented with 25 mM HEPES was added and the cell suspension was centrifuged at  
700 rpm and 19 °C for 5 min. The cell pellet was suspended in CHO serum-free medium supplemented 
with 25 mM HEPES and centrifuged again in the same conditions. Finally, the cells were washed with 
EC solution twice and suspended at a concentration of 20 × 106 cells/ml in EC solution for automated 
patch clamp experiments. Cell viability was always higher than 99% as determined by trypan blue 
exclusion test. 
In order to record hERG currents the voltage protocol applied was as follows: cells were clamped  
at −80 mV for 100 ms, pulsed to −100 mV for 90 ms and to −50 mV for 50 ms, then depolarized to  
+20 mV for 5 s and repolarized to −50 mV for 5 s, and finally returned to −80 mV. HERG currents were 
measured for 300 s after compound application. All experiments were done at 22 °C. 
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3.4. Animals and in vivo Experimental Design 
In vivo studies were performed with Sprague Dawley female rats of 8–16 weeks of age that weighted 
between 180 and 260 g. The rats were anesthetized with isoflurane and two catheters were placed in the 
jugular veins, one for compound administration and sample collection, and the other one for fluid therapy 
maintenance (5 mL/h). ECG recordings were obtained using lead II. The electrodes were placed on the 
skin, the negative and positive electrodes were on the right forelimb and on the left hind limb 
respectively. After surgical manipulation, a period of 15 min lapsed before recording basal ECG in order 
to ensure stable vital signs. Once the stabilization period was finished, ECG was recorded for 10 min. 
Then the toxin was administered by intravenous injection. For intravenous injection the solvent of each 
stock solution (methanol) was evaporated and the toxin was reconstituted in DMSO. Saline solution was 
added subsequently to provide a final concentration of 8 μg/mL OA, 6.4 μg/mL DTX-1 and 14 μg/mL 
YTX with a final DMSO concentration of 4% in all solutions. Nine control rats were injected with the 
same concentration of carrier (DMSO) in saline solution. Blood samples (400 µL) were collected in 
EDTA tubes right before (control of individual basal levels) and every hour after toxin administration for 
the detection of cardiac damage biomarkers in plasma. Blood samples (500 µL) were also collected in 
heparin tubes before toxin administration (control of individual basal levels) and at the end of each 
experiment for biochemical analysis. All experiments lasted for 240 min after toxin administration, 
except when the animals died during the experiment. All animal procedures were conducted according 
to the principles approved by the Institutional Animal Care Committee of the Universidad de Santiago 
de Compostela. 
3.5. Electrocardiography 
Lead II ECG was recorded at several times during the experiment and every recording period lasted 
for at least 10 min. An ECG recording was obtained before toxin administration (after the stabilization 
period) in every experiment and evaluated for alterations. Any abnormality detected in the ECG at this 
time prompted the interruption of the experiment. After toxin administration, ECG recordings were 
obtained starting at times 0 min, 50 min, 110 min, 170 min and 230 min. ECG recording speed was  
25 mm/s with intervals of 50 mm/s. Heart rate (HR) was evaluated by counting QRS complexes  
per min. PR interval was measured from P wave onset to QRS complex onset. Duration of QT interval 
was determined from the onset of QRS complex to the end of T wave. Q waves are often not present in 
rat ECG, therefore the base of the R wave is used in rodent models as a surrogate for the Q wave [27]. 
The length and morphology of T waves were evaluated when possible. All intervals were measured at a 
recording speed of 50 mm/s (Figure 3A). For PR interval, QT interval and T wave length evaluation, six 
consecutive measurements were done at three non-consecutive, randomly chosen points of every 10 min 
ECG recording (t-10, t0, t50, t110, t170 and t230). The results are reported for every interval as  
mean ± standard error of the mean (SEM) of the three randomly selected segments. QT interval was 
corrected using normalized Bazett’s equation like in previously published studies [36]. The same 
procedure was followed in control experiments for rats injected with carrier (DMSO) in the absence  
of toxin. 
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3.6. Cardiac Biomarkers 
Cardiac TnI, cTnT and BNP were measured in plasma samples of rats treated with OA, DTX-1 or 
carrier using a commercial assay based on the Luminex XMap® technology. Cardiac TnI in plasma 
samples of rats treated with YTX or carrier was determined using a specific ELISA kit. All blood samples 
collected during in vivo experiments were centrifuged immediately after collection to separate the plasma 
fraction. Plasma samples were stored at −80 °C until their analysis. The commercial Luminex assay is a 
panel of 3 immunoassays that allows the simultaneous and specific detection of the three rat cardiac 
biomarkers, cTnI, cTnT and BNP (rat cardiovascular disease panel 1, CVD Milliplex® Map KIT 
Millipore®) in plasma samples (100 µL). The ELISA kit is a high sensitivity assay for the determination 
of cTnI in plasma samples (50 µL). Both assays were done following the instructions provided by the 
manufacturers. All samples were assayed in duplicate. 
3.7. Biochemistry Analysis 
Several biochemistry parameters were analyzed in plasma samples collected during in vivo experiments 
and processed in the same way as the plasma samples used for detecting cardiac biomarkers. The analysis 
was done with the IDEXX VetTest® Chemistry Analyzer. A prepacked panel called General Health 
Profile (GHP) was used to test a total of 11 parameters: albumin (ALB), alkaline phosphatase (ALKP) 
alanine aminotransferase (ALT), blood urea nitrogen (BUN), calcium (Ca), cholesterol (CHOL), creatine 
kinase (CK), creatinine (CREA), globulin (GLOB), phosphorus (PHOS), and total protein (TP). 
3.8. Data Analysis 
Data were plotted as mean ± SEM. Statistical significance was determined by using t test for unpaired 
data and ANOVA for multiple comparisons. p < 0.05 was considered for significance. Sample size was 
calculated using the following equation: N = 2 × [((Zα + Zβ)2 × σ2)/Δ2)] where N is sample size, σ is the 
estimated value of standard deviation for population, Δ is the maximum difference between means and 
Zα and Zβ are constant values which depend on tail number (2), statistical significance level (5%) and 
potency (90%) of the analysis. 
4. Conclusions 
The evaluation of OA, DTX-1 and YTX cardiotoxicity indicated that none of these toxins exerted 
acute functional effects on hERG channel activity in vitro or on cardiac biomarkers and ECG in rats  
in vivo. The absence of acute functional effects for YTX, in spite of the reported ultrastructural 
alterations of heart tissue, suggests a short-term compensation. The implications of this ultrastructural 
damage in heart function for longer periods of exposure to the toxin should be explored because 
functional compensation may not be sustainable in the long term. Presently, no human reports have been 
related to cardiac dysfunctions; however, it should be considered that human exposure to the toxin has 
been limited by the legal regulation that establishes a maximum content of YTX in shellfish destined to 
human consumption of 1 mg/kg. Hence, these studies are critical for the evaluation of the risks associated 
to YTX consumption, mostly considering that the regulatory limit for this toxin in seafood has been 
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recently raised from 1 to 3.75 mg of YTX equivalents/kg of shellfish meat, and exposure of humans to 
the toxin will be increased [48]. 
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